磷酸奥司他韦联合布地奈德及特布他林治疗婴幼儿病毒性肺炎的疗效研究(1)
【摘要】 目的 探討磷酸奥司他韦联合布地奈德、特布他林治疗婴幼儿病毒性肺炎的临床疗效。方法 66例婴幼儿病毒性肺炎患儿， 随机分为对照组和观察组， 各33例。对照组患儿采用布地奈德、特布他林雾化吸入治疗， 观察组患儿采用磷酸奥司他韦联合布地奈德、特布他林治疗。比较两组患儿临床疗效、各项症状改善时间， 治疗前后超敏C反应蛋白(hs-CRP)、T淋巴细胞亚群及不良反应发生情况。结果 观察组患儿治疗总有效率96.97%高于对照组的81.82%;观察组患儿的咳嗽、发热、啰音、气喘消失时间分别为(6.24±0.83)、(3.05±1.13)、(5.02±1.09)、(5.78±0.81)d， 均短于对照组的(7.02±1.26)、(3.94±1.21)、(5.86±1.12)、(6.53±0.86)d;治疗后， 观察组患儿血hs-CRP水平(5.19±1.89)mg/ml低于对照组的(6.61±2.02)mg/ml;治疗后， 观察组患儿CD3+、CD4+、CD4+/CD8+水平分别为(65.24±6.82)%、(40.52±4.25)%、(1.35±0.24)高于对照组的(60.03±6.15)%、(37.17±4.21)%、(1.14±0.19)， CD8+水平(28.24±5.54)%低于对照组的(35.91±6.35)%， 差异均具有统计学意义 (P<0.05)。两组患儿不良反应发生率比较， 差异无统计学意义(P>0.05)。结论 磷酸奥司他韦联合布地奈德、特布他林治疗婴幼儿病毒性肺炎的疗效确切， 降低炎症因子， 提高免疫功能， 且患儿安全性高。
【关键词】 磷酸奥司他韦;布地奈德;特布他林;婴幼儿病毒性肺炎
DOI：10.14163/j.cnki.11-5547/r.2020.23.001
【Abstract】 Objective To discuss the clinical effect of oseltamivir phosphate combined with budesonide and terbutaline in the treatment of infantile viral pneumonia. Methods A total of 66 cases of infantile viral pneumonia were randomly divided into control group and observation group， with 33 cases in each group. The control group was treated with budesonide and terbutaline inhalation， while the observation group was treated with oseltamivir phosphate combined with budesonide and terbutaline. The clinical efficacy， improvement of clinical symptoms， high sensitivity C-reactive protein (hs-CRP) and T lymphocyte subsets before and after treatment and occurrence of adverse reactions was compared between the two groups. Results The total effective rate of treatment 96.97% of the observation group was higher than that of the control group. The disappearance time of cough， fever， rales and asthma of the observation group was (6.24±0.83)， (3.05±1.13)， (5.02±1.09) and (5.78±0.81)d， which was shorter than that of the control group (7.02±1.26)， (3.94±1.21)， (5.86±1.12) and (6.53±0.86)d. After treatment， hs-CRP (5.19±1.89) mg/ml of the observation group was lower than that of the control group (6.61±2.02) mg/ml. After treatment， CD3+， CD4+ and CD4+/CD8+ of the observation group was (65.24±6.82)%， (40.52±4.25)% and (1.35±0.24) respectively， which was higher than that of the control group (60.03±6.15)%， (37.17±4.21)% and (1.14±0.19)， and CD8+ (28.24±5.54)% was lower than that of the control group (35.91±6.35)%， and the difference was statistically significant (P<0.05). There was no statistically significant difference in incidence of adverse reactions between the two groups (P>0.05). Conclusion Oseltamivir phosphate combined with budesonide and terbutaline shows affirmative effect in the treatment of infantile viral pneumonia， which can reduce inflammatory factors and improve immune function with high safety in children., http://www.100md.com(黎敏 邱华 黄志勇)
【关键词】 磷酸奥司他韦;布地奈德;特布他林;婴幼儿病毒性肺炎
DOI：10.14163/j.cnki.11-5547/r.2020.23.001
【Abstract】 Objective To discuss the clinical effect of oseltamivir phosphate combined with budesonide and terbutaline in the treatment of infantile viral pneumonia. Methods A total of 66 cases of infantile viral pneumonia were randomly divided into control group and observation group， with 33 cases in each group. The control group was treated with budesonide and terbutaline inhalation， while the observation group was treated with oseltamivir phosphate combined with budesonide and terbutaline. The clinical efficacy， improvement of clinical symptoms， high sensitivity C-reactive protein (hs-CRP) and T lymphocyte subsets before and after treatment and occurrence of adverse reactions was compared between the two groups. Results The total effective rate of treatment 96.97% of the observation group was higher than that of the control group. The disappearance time of cough， fever， rales and asthma of the observation group was (6.24±0.83)， (3.05±1.13)， (5.02±1.09) and (5.78±0.81)d， which was shorter than that of the control group (7.02±1.26)， (3.94±1.21)， (5.86±1.12) and (6.53±0.86)d. After treatment， hs-CRP (5.19±1.89) mg/ml of the observation group was lower than that of the control group (6.61±2.02) mg/ml. After treatment， CD3+， CD4+ and CD4+/CD8+ of the observation group was (65.24±6.82)%， (40.52±4.25)% and (1.35±0.24) respectively， which was higher than that of the control group (60.03±6.15)%， (37.17±4.21)% and (1.14±0.19)， and CD8+ (28.24±5.54)% was lower than that of the control group (35.91±6.35)%， and the difference was statistically significant (P<0.05). There was no statistically significant difference in incidence of adverse reactions between the two groups (P>0.05). Conclusion Oseltamivir phosphate combined with budesonide and terbutaline shows affirmative effect in the treatment of infantile viral pneumonia， which can reduce inflammatory factors and improve immune function with high safety in children., http://www.100md.com(黎敏 邱华 黄志勇)